Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 17/20 | 0.72 |
| ▸ | ABL2 | P42684 | 8/20 | 0.72 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.72 |
| ▸ | BCR | P11274 | 2/20 | 0.56 |
| ▸ | SRC | P12931 | 4/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.54 |
| ▸ | MLNR | O43193 | 1/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19317716 | 0.93 | ABL1 (0.78) | ABL1ABL2MAPK14BCRSRC | |
| SCHEMBL24449244 | 0.92 | ABL1 (0.75) | ABL1ABL2MAPK14BCRSRC | |
| SCHEMBL19316723 | 0.88 | ABL1 (0.72) | ABL1ABL2MAPK14BCRSRC | |
| SCHEMBL19317673 | 0.84 | ABL1 (1.00) | ABL1ABL2MAPK14BCRSRC | |
| SCHEMBL19316720 | 0.80 | ABL1 (0.75) | ABL1ABL2MAPK14BCRSRC | |
| SCHEMBL19317713 | 0.80 | ABL1 (0.78) | ABL1ABL2MAPK14SRCNTRK1 | |
| SCHEMBL19316722 | 0.80 | ABL1 (0.58) | ABL1ABL2MAPK14SRCNTRK1 | |
| SCHEMBL24448260 | 0.80 | ABL1 (0.73) | ABL1ABL2MAPK14SRCNTRK1 | |
| SCHEMBL9610728 | 0.79 | ABL1 (0.74) | ABL1ABL2MAPK14BCRSRC | |
| SCHEMBL19317707 | 0.79 | ABL1 (0.64) | ABL1ABL2MAPK14SRCRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | PTGES, PTGS1, PTGES2 | ABL1 4516/4885ABL2 2755/4885MAPK14 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.